Back to top
more

Veracyte (VCYT)

(Delayed Data from NSDQ)

$19.31 USD

19.31
629,746

-0.17 (-0.87%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $19.30 -0.01 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (94 out of 252)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Veracyte's (VCYT) Q4 Loss Widens, Gross Margin Expands

Veracyte's (VCYT) fourth-quarter 2023 performance reflects solid financial discipline and the strength of the Decipher Prostate and Afirma tests.

Veracyte (VCYT) Reports Q4 Loss, Tops Revenue Estimates

Veracyte (VCYT) delivered earnings and revenue surprises of 42.86% and 2.84%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

3 Medical Instruments Stocks to Buy as Industry Trends Improve

The Zacks Medical - Instruments industry is gaining from the rising demand for digital health offers. However, inflation and staffing shortages continue to disrupt growth. HOLX, MASI and VCYT appear well-poised to brave the challenges.

The Zacks Analyst Blog Highlights Palantir Technologies, Veracyte, PagerDuty, Roku and UiPath

Palantir Technologies, Veracyte, PagerDuty, Roku and UiPath are part of the Zacks top Analyst Blog.

Aniruddha Ganguly headshot

5 Top-Ranked Cathie Wood Stocks to Buy Right Now

Here, we have picked five Cathie Wood stocks, Palantir (PLTR), Veracyte (VCYT), PagerDuty (PD), Roku (ROKU) and UiPath (PATH), which are well-poised for healthy returns in 2024.

Veracyte (VCYT) Reports Q2 Loss, Tops Revenue Estimates

Veracyte (VCYT) delivered earnings and revenue surprises of 25% and 7.60%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

RxSight, Inc. (RXST) Reports Q2 Loss, Tops Revenue Estimates

RxSight, Inc. (RXST) delivered earnings and revenue surprises of 14.89% and 8.36%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Pacific Biosciences of California (PACB) Reports Q2 Loss, Tops Revenue Estimates

Pacific Biosciences (PACB) delivered earnings and revenue surprises of 23.53% and 17.95%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Veracyte (VCYT) Reports Q1 Loss, Tops Revenue Estimates

Veracyte (VCYT) delivered earnings and revenue surprises of 21.43% and 6.94%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Will Veracyte (VCYT) Report Negative Earnings Next Week? What You Should Know

Veracyte (VCYT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wall Street Analysts See a 40.19% Upside in Veracyte (VCYT): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 40.2% in Veracyte (VCYT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Veracyte (VCYT) Reports Q4 Loss, Tops Revenue Estimates

Veracyte (VCYT) delivered earnings and revenue surprises of 66.67% and 6.28%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Best Momentum Stocks to Buy for January 24th

VIPS, VCYT and EVR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 24, 2023.

Terex and Armstrong World Industries have been highlighted as Zacks Bull and Bear of the Day

Terex and Armstrong World Industries are part of the Zacks Bull and Bear of the Day article.

Indrajit Bandyopadhyay headshot

3 Medical Instruments Stocks on Recovery Path After Dismal 2022

Here we discuss three medical instruments stocks - TCMD, VCYT and NVCN - that have started to recover in the past few months after declining for the major part of 2022.

What Makes Veracyte (VCYT) a New Buy Stock

Veracyte (VCYT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Veracyte (VCYT) Reports Q3 Loss, Tops Revenue Estimates

Veracyte (VCYT) delivered earnings and revenue surprises of 50% and 12.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Veracyte (VCYT) Reports Q2 Loss, Tops Revenue Estimates

Veracyte (VCYT) delivered earnings and revenue surprises of 38.10% and 8.15%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Wall Street Analysts Predict a 41% Upside in Veracyte (VCYT): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 41.2% in Veracyte (VCYT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Veracyte (VCYT) Reports Q1 Loss, Tops Revenue Estimates

Veracyte (VCYT) delivered earnings and revenue surprises of 13.04% and 9.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Veracyte (VCYT) Reports Q4 Loss, Tops Revenue Estimates

Veracyte (VCYT) delivered earnings and revenue surprises of -7.14% and 6.07%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Inogen (INGN) Reports Q4 Loss, Misses Revenue Estimates

Inogen (INGN) delivered earnings and revenue surprises of -36.49% and 0.04%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

DexCom (DXCM) Q4 Earnings Lag Estimates

DexCom (DXCM) delivered earnings and revenue surprises of -20.93% and 0.03%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Veracyte (VCYT) Report Negative Q4 Earnings? What You Should Know

Veracyte (VCYT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Thermo Fisher Scientific (TMO) Surpasses Q4 Earnings and Revenue Estimates

Thermo Fisher (TMO) delivered earnings and revenue surprises of 25.29% and 18.56%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?